Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology firm Advaxis has signed an agreement with SynCo Bio Partners for manufacturing of its lead cancer immunotherapy program.
Subscribe to our email newsletter
Under the deal, SynCo will manufacture Advaxis’ novel drug candidate, ADXS-HPV as well as assist them in developing scale-up and commercial manufacturing processes for ADXS-HPV bulk drug substance and drug product.
The company also intends to begin registrational trials in 2014 with ADXS-HPV for the treatment of cervical cancer.
Advaxis chief executive officer Daniel O’Connor said SynCo’s ability to manufacture both drug substance and drug product for ADXS-HPV will offer the company increased flexibility as it expands its manufacturing process in preparation for commercial-scale production.
"To have the support of a world class manufacturer, such as SynCo, is pivotal to our ability to make ADXS-HPV available to patients on a global scale, upon approval," O’Connor said.
In a Phase II trial, ADXS-HPV has showed improved survival and objective tumor responses in 110 patients with recurrent cervical cancer.
Currently, the company is now planning the registrational program for ADXS-HPV, which is also being assessed in other HPV-associated cancers including a Phase II in advanced cervical cancer, a Phase I/II in head and neck cancer, and a Phase I/II in anal cancer.
The company said that ADXS-HPV has received orphan drug designation for both anal and head and neck cancers.